000 04216nam a22004335c 4500
999 _c6818
_d6818
001 6818
003 ES-MaUEC
005 20200630160452.0
006 a||||fo|||| 00| 0
007 cr nn 008mamaa
008 181212s2019 gw a s |||| 0|eng d
020 _a9783030012076
024 7 _a10.1007/978-3-030-01207-6
_2doi
040 _bspa
_cES-MaUEC
_dES-MaUEC
050 4 _aRC254.5
_b.R44 2019EB
245 0 0 _aRegulatory and Economic Aspects in Oncology
_cedited by Evelyn Walter.
264 1 _aCham
_bSpringer International Publishing :
_bImprint: Springer
_c2019.
300 _aVII, 205 páginas 14 ilustraciones, 12 ilustraciones a color
336 _2rdacontent
_aTexto (visual)
_btxt
337 _2rdamedia
_aelectrónico
_bc
338 _2rdacarrier
_arecurso electrónico
_bcr
347 _atext file
_bPDF
_2rda
490 1 _aRecent Results in Cancer Research,
_x0080-0015 ;
_v213
490 0 _aMedicine (Springer-11650)
505 0 _aThe growing health burden of cancer: a global epidemiological overview.-Cost of Cancer Care: Health expenditures and economic impact -- Innovation in R&D: An answer to cancer -- The Evaluation of Benefits, Harms and Costs of Cancer Screening -- Oncology from a HTA and health economic perspective -- Heterogeneous recommendations for oncology products among different HTA systems: a comparative assessment -- Outcomes in oncology: clinical vs. patient-reported outcome performance measures -- The value of patient-reported outcome in health economic decision making: a changing landscape in oncology -- Approaches to capture value in oncology -- Orphan durgs in oncology -- Recent developments in health economic modeling of cancer therapies -- Drug pricing and value in oncology -- Pharmaceutical price regulation of cancer treatments -- Regulatory and evidence requirements and the changing landscape in regulation for marketing authorization -- Looking for Willingness to Pay (WTP) Threshold for a QALY in oncology -- Equity and patient access to innovative cancer treatments. .
520 3 _aThis book explores a wide range of topics of importance to all those who have an interest in economic methods for assessment of the efficacy and effectiveness of new cancer treatments and in regulatory measures relating to the marketing authorization and pricing of such treatments. It also examines drug pricing and drug price regulation in different countries and explores the changing landscape in marketing authorization and its regulation. These issues are becoming increasingly important with the introduction of expensive targeted cancer therapies, which are placing a substantial strain on healthcare healthcare budgets. Payer authorities have to determine whether the use of targeted therapies yields clinical benefits that justify their cost. In the simplest terms, cost-effectiveness analysis quantifies the ratio between the extent to which an intervention raises healthcare costs and the extent to which it improves health outcomes. Rigorous cost-effectiveness analyses translate all health outcomes into quality-adjusted life years. On the other hand, in order to sustain innovation, price regulation must be coupled with efforts to ensure that drug companies are still able to recoup their investments in high-risk and high-cost research programs. Ultimately, decisions regarding health care expenditure are also a reflection of society’s willingness to pay.
988 _aPrimersemestre_2019_Medicine
650 1 4 _aOncology.
_0http://scigraph.springernature.com/things/product-market-codes/H33160
653 0 _aOncology  .
653 0 _aPractice of medicine.
700 1 _aWalter, Evelyn.
_eeditor literario
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
710 2 _aSpringerLink (Online service)
_9106937
776 0 8 _iPrinted edition:
_z9783030012069
776 0 8 _iPrinted edition:
_z9783030012083
830 0 _aRecent Results in Cancer Research,
_x0080-0015 ;
_v213
856 4 0 _uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-01207-6
_zAcceso a este recurso digital (usuarios Universidad Europea de Valencia)
942 _2lcc
_cLE
998 _db
_feng
_ggw
_h0
_el